Antivirals and vaccines for Enterovirus A71

Area of Science:

• Virology
• Infectious Diseases
• Public Health

Background:

• Enterovirus A71 (EV-A71) is a significant emerging pathogen, primarily affecting children under five.
• EV-A71 infections can lead to hand-foot-and-mouth disease, herpangina, and severe neurological complications.
• Currently, no effective antiviral treatments are available for EV-A71 infections.

Purpose of the Study:

• To review antiviral compounds targeting the EV-A71 life cycle.
• To summarize the development and clinical progress of various EV-A71 vaccine candidates.
• To provide an overview of strategies for combating EV-A71.

Main Methods:

• Literature review of antiviral compounds targeting EV-A71.
• Analysis of clinical trial data and development status of EV-A71 vaccines.
• Synthesis of information on different vaccine platforms, including inactivated virus, recombinant protein, peptide, viral-like particle, and live attenuated vaccines.

Main Results:

• Several antiviral compounds targeting different stages of the EV-A71 life cycle have been developed.
• Multiple EV-A71 vaccine candidates are in various stages of development and clinical trials.
• Diverse vaccine approaches are being explored, indicating active research efforts.

Conclusions:

• Antiviral drug development for EV-A71 is ongoing, addressing the lack of effective treatments.
• Vaccine development is crucial for preventing EV-A71 infections, with several promising candidates.
• Continued research into both antivirals and vaccines is essential to control EV-A71 outbreaks.